# Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies

> **NCT01724528** · PHASE3 · COMPLETED · sponsor: **Menarini Group** · enrollment: 346 (actual)

## Conditions studied

- Tumor Lysis Syndrome

## Interventions

- **DRUG:** Febuxostat
- **DRUG:** Allopurinol

## Key facts

- **NCT ID:** NCT01724528
- **Lead sponsor:** Menarini Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 346 (ACTUAL)
- **Last updated:** 2014-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01724528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01724528, "Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01724528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*